Shares of Shaily Engineering Plastics Limited rose 3.59% to Rs 1,730.00 on Tuesday after the company reported a sharp rise in earnings for Q1 FY26, driven by robust growth in its healthcare segment. The stock touched an intraday high of Rs 1,866.60, compared to its previous close of Rs 1,670.00, valuing the company at Rs 7,956 crore.
For the April–June quarter, revenue jumped 38% year-on-year (YoY) to Rs 246.7 crore from Rs 179.4 crore in Q1 FY25. EBITDA rose 95% YoY to Rs 70.4 crore, with margins improving by 840 basis points to 28.5%. Net profit more than doubled, surging 136% YoY to Rs 41.1 crore, while cash PAT increased 91% to Rs 52.6 crore.
Segment-wise, healthcare revenue soared 181% YoY to Rs 77.2 crore, supported by the official start of commercial manufacturing of GLP-1 pens for semaglutide. The consumer segment grew 14% YoY to Rs 151.4 crore, while industrial revenue slipped 6% YoY to Rs 18.1 crore. The company stated that 50–60% of its expanded pen production capacity is backed by customer commitments.
Management expects healthcare to make a significant contribution to revenue and profitability over the next couple of years, with capacity expansions of up to 80 million pens per year in progress.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.